CN116426648A - 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 - Google Patents
一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 Download PDFInfo
- Publication number
- CN116426648A CN116426648A CN202310304032.XA CN202310304032A CN116426648A CN 116426648 A CN116426648 A CN 116426648A CN 202310304032 A CN202310304032 A CN 202310304032A CN 116426648 A CN116426648 A CN 116426648A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- exosomes
- mirna
- mir
- cell exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 73
- 239000002679 microRNA Substances 0.000 title claims abstract description 45
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 44
- 108091070501 miRNA Proteins 0.000 title claims abstract description 42
- 238000011529 RT qPCR Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 14
- 108091084619 miR-125b-1 stem-loop Proteins 0.000 claims abstract description 9
- 108091091751 miR-17 stem-loop Proteins 0.000 claims abstract description 9
- 108091029500 miR-183 stem-loop Proteins 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 abstract description 11
- 239000002245 particle Substances 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108091058866 miR-183-1 stem-loop Proteins 0.000 description 1
- 108091045731 miR-183-2 stem-loop Proteins 0.000 description 1
- 108091043778 miR-183-3 stem-loop Proteins 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
Abstract
Description
引物名称 | 引物序列(5'--3') |
miR-183-1 | CCGCAGAGTGTGACTCCTGT |
miR-183-2 | AGCAGAGACAGATCCACGA |
miR-183-3 | CACTGTGAACAGTCTCAGTCA |
miR-183-4 | ACTGGTAGAATTCACTGTGAAC |
引物名称 | 引物序列(5'--3') |
miR-17-3p-1 | GTCAGAATAATGTCAAAGTGC |
miR-17-3p-2 | ACTGCAGTGAAGGCACTTGTA |
miR-17-3p-3 | AAAGTGCTTACAGTGCAGGTA |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310304032.XA CN116426648B (zh) | 2023-03-27 | 2023-03-27 | 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310304032.XA CN116426648B (zh) | 2023-03-27 | 2023-03-27 | 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116426648A true CN116426648A (zh) | 2023-07-14 |
CN116426648B CN116426648B (zh) | 2024-03-08 |
Family
ID=87093617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310304032.XA Active CN116426648B (zh) | 2023-03-27 | 2023-03-27 | 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116426648B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105360A1 (en) * | 2004-02-09 | 2006-05-18 | Croce Carlo M | Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features |
CN104321062A (zh) * | 2012-04-03 | 2015-01-28 | 兰诺龙有限公司 | 干细胞微粒 |
CN108938659A (zh) * | 2017-05-19 | 2018-12-07 | 昆山彭济凯丰生物科技有限公司 | 一种调节食欲和体重的方法和药物及它们的应用 |
CN109913547A (zh) * | 2019-03-01 | 2019-06-21 | 浙江大学医学院附属妇产科医院 | 一种血浆外泌体miRNA分子标志物及其在制备试剂盒中的应用 |
CN109996888A (zh) * | 2016-09-23 | 2019-07-09 | 阿尔韦奥科技公司 | 用于检测分析物的方法和组合物 |
CN111662982A (zh) * | 2020-06-09 | 2020-09-15 | 山东大学齐鲁医院 | 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用 |
CN113151461A (zh) * | 2021-02-25 | 2021-07-23 | 河北大学附属医院 | 一种miRNA-183-5p基因的检测引物及其应用 |
CN114540297A (zh) * | 2022-03-22 | 2022-05-27 | 深圳市儿童医院 | 一种间充质干细胞外泌体的分离和miRNA分析方法 |
CN115011686A (zh) * | 2021-06-11 | 2022-09-06 | 中国人民解放军空军军医大学 | 一种基于血清外泌体miRNA的PD诊断及分期试剂盒 |
CN115040543A (zh) * | 2021-03-08 | 2022-09-13 | 上海赛立维生物科技有限公司 | 外泌体制剂在制备肝衰竭治疗类药物方面的应用 |
-
2023
- 2023-03-27 CN CN202310304032.XA patent/CN116426648B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105360A1 (en) * | 2004-02-09 | 2006-05-18 | Croce Carlo M | Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features |
CN104321062A (zh) * | 2012-04-03 | 2015-01-28 | 兰诺龙有限公司 | 干细胞微粒 |
CN109996888A (zh) * | 2016-09-23 | 2019-07-09 | 阿尔韦奥科技公司 | 用于检测分析物的方法和组合物 |
CN108938659A (zh) * | 2017-05-19 | 2018-12-07 | 昆山彭济凯丰生物科技有限公司 | 一种调节食欲和体重的方法和药物及它们的应用 |
CN109913547A (zh) * | 2019-03-01 | 2019-06-21 | 浙江大学医学院附属妇产科医院 | 一种血浆外泌体miRNA分子标志物及其在制备试剂盒中的应用 |
CN111662982A (zh) * | 2020-06-09 | 2020-09-15 | 山东大学齐鲁医院 | 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用 |
CN113151461A (zh) * | 2021-02-25 | 2021-07-23 | 河北大学附属医院 | 一种miRNA-183-5p基因的检测引物及其应用 |
CN115040543A (zh) * | 2021-03-08 | 2022-09-13 | 上海赛立维生物科技有限公司 | 外泌体制剂在制备肝衰竭治疗类药物方面的应用 |
CN115011686A (zh) * | 2021-06-11 | 2022-09-06 | 中国人民解放军空军军医大学 | 一种基于血清外泌体miRNA的PD诊断及分期试剂盒 |
CN114540297A (zh) * | 2022-03-22 | 2022-05-27 | 深圳市儿童医院 | 一种间充质干细胞外泌体的分离和miRNA分析方法 |
Non-Patent Citations (3)
Title |
---|
SHUO FANG ET AL.: "Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-b/SMAD2 Pathway During Wound Healing", TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 5, pages 1426 * |
方硕: "干细胞来源的外泌体对成纤维细胞向肌成纤维细胞分化的调控作用及其机制研究", 中国博士学位论文全文数据库 医药卫生科技辑, no. 2, pages 57 * |
林庆铿 等: "第2代和第5代人脐带间充质干细胞外泌体miRNA谱的比较", 中国组织工程研究, vol. 22, no. 17, pages 2687 * |
Also Published As
Publication number | Publication date |
---|---|
CN116426648B (zh) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110191962A (zh) | 外来体相关核酸的测序和分析 | |
US9353413B2 (en) | Internal reference genes for microRNAs normalization and uses thereof | |
US20180142295A1 (en) | Regulator targeting fatty acid synthase and method of using the same for improving meat quality | |
CN108676894A (zh) | 与猪胴体肉品质相关的circRNA标志物及其应用 | |
CN110804659A (zh) | 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用 | |
CN107385037B (zh) | 一种miRNA间接实时荧光定量PCR检测方法 | |
CN116426648B (zh) | 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物 | |
CN109207634A (zh) | 海州常山干旱胁迫下荧光定量内参基因及其专用引物和应用 | |
CN115873937B (zh) | 一种预测反复种植失败发生的生物标志物及其应用 | |
CN113980968B (zh) | 一种新的ra标志长链非编码rna及其应用 | |
CN109136382B (zh) | 一种对四种人体体液来源进行鉴定的方法和*** | |
CN109266741B (zh) | 一种膀胱癌干细胞鉴定的试剂盒及其应用 | |
Remakova et al. | Validation of RNA extraction procedures focused on micro RNA expression analysis | |
CN111560429B (zh) | 一种用于地中海贫血诊断的circRNA标志物的应用 | |
CN110747268B (zh) | 一种血清外泌体ssc-miR-17-5p作为母猪早期妊娠诊断分子标志物的应用 | |
CN112195254A (zh) | 一种干扰mstn牛骨骼肌卫星细胞实时荧光定量pcr内参基因筛选的方法 | |
CN113549690B (zh) | 一种长链非编码rna及其作为多发性骨髓瘤细胞分子标志物的应用 | |
CN109402289B (zh) | 海州常山不同组织的荧光定量内参基因及其引物和应用 | |
CN110218795B (zh) | miR-766-3p和miR-766-5p在制备高级别胶质瘤和颅内淋巴瘤诊断和鉴别诊断制剂中的应用 | |
CN114107209B (zh) | 一种非治疗目的的高表达miR-146a-5p的外泌体抑制THP-1分化和巨噬细胞M1极化的方法 | |
CN114107449B (zh) | 一种单细胞内原位qPCR方法 | |
CN107254537A (zh) | miR‑1912及其靶基因在诊治心肌梗死中的应用 | |
CN109266780B (zh) | 海州常山盐胁迫下荧光定量内参基因及其引物和应用 | |
EP2615180B1 (en) | Method for the quantification, qualitative genetic characterization and gene expression characterization of predetermined cells | |
CN116121367A (zh) | 目标miRNA检测探针及其试剂盒与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240131 Address after: Building A10, No. 12 Biotech Valley Avenue, Torch Development Zone, Zhongshan City, Guangdong Province, 528400, 1st floor, 2nd floor, A1-A3, 3rd and 4th floors Applicant after: Aiyi Life Technology (Guangdong) Co.,Ltd. Country or region after: China Applicant after: Guangdong Kangbai Pharmaceutical Technology Co.,Ltd. Address before: Building A10, No. 12 Biotech Valley Avenue, Torch Development Zone, Zhongshan City, Guangdong Province, 528400, 1st floor, 2nd floor, A1-A3, 3rd and 4th floors Applicant before: Aiyi Life Technology (Guangdong) Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |